GleamWall
中文EN

SYRE Spyre Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1636282 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-77.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-35.0%
ROA-32.9%
ROIC (approx.)-29.1%
Asset turnover—

Leverage & solvency

Liabilities / assets4.4%
Debt / equity0.00x
Current ratio27.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$171.65M$162.79M
SG&A expense$47.91M$45.78M
Operating income-$209.56M-$208.57M
Pretax income-$155.22M-$207.97M
Income tax-$15,000$51,000
Net income-$155.20M-$208.02M
EBITDA-$209.56M-$208.57M
EPS (diluted)——
Balance sheet
Cash & equivalents$85.72M$89.42M
Short-term investments$670.81M$513.66M
Current assets$777.78M$608.47M
Total assets$777.78M$608.48M
Current liabilities$58.69M$54.06M
Total liabilities$62.55M$90.68M
Shareholders' equity$715.24M$517.80M
Shares outstanding78.19M60.26M
Cash flow statement
Operating cash flow-$169.25M-$157.41M
Capital expenditure—$0
Free cash flow—-$157.41M
Investing cash flow-$143.47M-$353.29M
Financing cash flow$309.02M$410.91M
Depreciation & amortization$0$0
Stock-based compensation$37.61M$44.83M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.